A fifty-four-year-old chief operating officer in Asokoro had a primary percutaneous coronary intervention at a private hospital off Aguiyi Ironsi Street eighteen months ago. The artery was the proximal left anterior descending. The stent was placed cleanly. The interventional cardiologist is one of the better hands in the country, and the discharge summary was written carefully — dual antiplatelet therapy for twelve months minimum, statin indefinitely, a beta-blocker, an ACE inhibitor, a six-week clinic review, and a six-month echocardiogram. He went home on a Friday in February 2025 with a stack of prescriptions and the felt belief that the worst part of his life was behind him. He was not wrong about the procedure. He was wrong about what came after it.
He took the medications faithfully for the first three months. At month four his clopidogrel ran out on a weekend when he was travelling to Port Harcourt, the pharmacy he tried did not stock it, he came back to Abuja on the Monday and decided he would buy it that week and forgot. At month six his cardiologist’s practice telephoned about the echocardiogram, except the practice had merged with another group and the consultant who knew him had moved facilities, and the call came from a number he did not recognise, and he did not return it. At month nine he was off the clopidogrel entirely, half-compliant on the statin, and convinced — because he felt well — that he had recovered. At month sixteen he collapsed in a meeting in Wuse II with crushing central chest pain and an ECG announcing acute in-stent thrombosis of the same vessel his cardiologist had so carefully reopened. He survived. The second stent was placed at a different hospital, by a different team, in a chart that did not contain the original procedure note.
He is not a non-compliant patient. He is an abandoned one.
This is not hypothetical. It is the operating model Nigerian medicine runs on, and the cost of it is paid quietly, in the months between visits, by patients who believe their care is continuing when in fact it has stopped.
The clinical encounter as an event, not a relationship
Default Nigerian healthcare treats the visit as the unit of care. The patient presents. The patient is investigated. The patient is treated. The patient is discharged. The visit ends, the file is closed, the folder is returned to the cabinet, and the patient walks out into the rest of their life carrying a sheaf of paper that they alone are responsible for translating into the next year of medical decisions. The clinician’s job, in the model that operates everywhere from the busiest teaching hospital to the most expensive private clinic in Maitama, ends at the door.
This is not how medicine has worked in any system that produces good outcomes for chronic disease. In every system that has actually moved the mortality numbers in the diseases that kill middle-aged Nigerians — ischaemic heart disease, hypertensive heart disease, type 2 diabetes, the breast and prostate and gastrointestinal cancers caught in time — what does the work is not the encounter. It is the months after the encounter. The follow-up call. The scheduled review. The repeat biochemistry. The titration of the medication that was started but not yet correct. The named clinician who notices the patient has not been seen and reaches for the phone.
That is the entire infrastructure of continuity. It is also the part default Nigerian care does not have.
A second story, in a different room
A thirty-nine-year-old marketing director in Ikoyi found a lump in her right breast in late 2023. She did the responsible thing — promptly. She saw a general surgeon at a private clinic on Bourdillon Road within two weeks. The ultrasound was suggestive of a fibroadenoma but recommended core biopsy. The biopsy was done. The pathology came back benign. The surgeon’s discharge note, in clear handwriting, said recommend repeat imaging in six months to confirm stability. She went home reassured. The result was negative. The conversation, in her mind, was closed.
Nobody called her at month six. The clinic did not run a recall system that flagged her for the repeat ultrasound. The surgeon who had biopsied her was, six months later, at a different hospital and had no list of patients to recall. Her GP — to the extent that the doctor she occasionally saw for malaria and travel vaccines could be called a GP — had never seen the histology report and did not know a follow-up was due. She had a benign biopsy. The system, having delivered the verdict, considered its work done.
Two years later, after a close friend was diagnosed with breast cancer at forty-one and she went in for what she meant to be a precautionary check, the lump had grown. The repeat imaging she should have had at month six was now happening at month twenty-six, and the lesion that had been a 1.4 centimetre well-circumscribed mass was now a 2.9 centimetre mass with indeterminate margins and a positive sentinel node. The cancer was caught. It was not caught early.
Her outcome, on present trajectory, is probably acceptable. The conversation she has with her oncologist for the next decade will, for the rest of her life, be a different conversation than the one she would have had with the same oncologist if the system had remembered her name in August 2024.
What follow-up actually does, clinically
The reason follow-up is the part of medicine that does the work is that almost every cardiometabolic and oncologic outcome improvement in modern practice depends on time, on iteration, and on the comparison of one moment with another. The single visit produces a snapshot. The relationship produces a trajectory, and trajectory is what disease is.
The international literature is unambiguous. Post-discharge mortality after a myocardial infarction falls substantially when patients are reviewed within two weeks of discharge. Adherence to chronically prescribed regimens drops by roughly half within the first three months without clinical contact — secondary-prevention statins, antihypertensives, oral hypoglycaemics, all in this range across the published meta-analyses. Cancer survival is in almost every site dominated by stage at diagnosis, and stage at diagnosis is dominated by the recall system the patient is or is not inside.
These are not soft numbers. They are the difference between living and dying. They are also numbers almost no Nigerian private practice is producing on its own patients, because the data that would produce them sits in paper folders in different filing cabinets in different buildings and has never been read in sequence.
Why Nigerian follow-up specifically fails
Three structural reasons sit underneath every story in this piece.
The first is that records are paper, in folders, in filing cabinets, in single buildings. Move the patient to another hospital — for the second stent, for the post-surgical complication, for the obstetric emergency — and the file does not move. The patient arrives in front of a new team carrying, at best, a discharge summary they may or may not have kept, a stack of medications they may or may not still be taking, and a verbal history they may or may not have the clinical vocabulary to convey. The team works from what is in the room. The team in the previous room is not consulted. The continuity, such as it ever was, ends at the building’s perimeter.
The second is that physicians rotate. The named consultant on the discharge summary is frequently not at the same hospital six months later. Private cardiology, oncology, and general surgery in Abuja and Lagos run substantially on consultants with practising rights at multiple facilities, who move between them on schedules driven by each facility’s operating economics. A patient discharged in February by a cardiologist visiting the hospital that month may, by August, find the cardiologist no longer attends, and the discharging system has no native mechanism to forward the patient on. The relationship was the cardiologist’s, not the institution’s, and when the cardiologist moves the relationship dissolves.
The third is that there is no continuous primary-care relationship for most Nigerian adults. The GP, in the sense the British or American word implies — the clinician who has standing to coordinate, to recall, to follow up, to chase the missing investigation, to be the one constant in the patient’s clinical life — does not exist as a category for most of the population. The hospital is where care happens. Between hospital visits there is no clinician. The hospital, having discharged, is done. The patient, having been discharged, is alone.
What the hidden cost actually is
The cost is not exotic. It is the predictable accumulation of what happens when chronic disease management is left to people who did not train to manage chronic disease — namely, the patients themselves.
It is late diagnoses that turn terminal. The breast lump caught at twenty-six months instead of six. The colonoscopy that was recommended after a hemicolectomy and never scheduled. The PSA trend that was rising for three years before the metastatic lesion announced itself in a vertebral body.
It is medication regimens that silently drift. The post-MI patient who is off his clopidogrel by month nine. The hypertensive whose amlodipine was started at five milligrams and was supposed to be titrated to ten and has been at five for three years. The diabetic whose metformin worked for two years and now does not and who has never been reviewed for the second-line agent he needed eighteen months ago.
It is post-surgical complications caught in A&E rather than in clinic. The wound infection that became sepsis because the post-operative review at week two did not happen. The thyroid replacement dose that was started after a hemithyroidectomy and never adjusted, and the patient who has been hypothyroid for fourteen months and thought it was the Lagos traffic making her tired.
It is the diagnostic moments thrown away because there was no relationship to return them to. The biopsy result the patient never picked up because nobody called. The imaging report that was filed but never read against the previous year’s study. The blood test that flagged an abnormality at the bottom of page two that nobody on either side of the desk ever turned to.
And it is the cost the families pay, which does not show up in any statistic. The daughter in Houston who realises, after her mother’s second admission, that no doctor has been in her mother’s life for the eighteen months between the first admission and the second. The wife who learns, the morning her husband collapses, that the cardiologist she thought was managing him moved practices a year ago and nobody told her. The children who discover, after the funeral, that the parent they assumed was being looked after had been, for most of two years, looking after themselves.
What follow-up properly designed looks like
The corrective is not exotic either. It is the standard of care everywhere else, applied here.
It is a named physician who carries the file across the lifetime of the relationship, in a single record system that does not depend on which building the patient happens to be standing in. It is scheduled follow-up that does not depend on the patient remembering the date, because the practice remembers the date and the practice calls. It is a WhatsApp line — the unglamorous, deeply useful, characteristically Nigerian asynchronous channel — for the question the patient is too embarrassed to phone the consultant about. It is coordination of the next investigation, the refill that is about to run out, the specialist visit that the discharge summary recommended and that nobody has yet scheduled. It is a clinician who has standing to chase the missing result, the unread report, the appointment the patient did not attend. It is records held in one system across the relationship’s lifetime, so that the trajectory of one human being’s health is legible to the person responsible for managing it.
That description sounds modest. It is, in the Nigerian context, almost revolutionary. The infrastructure to deliver it has only recently become viable, and the patients who most need it have, until very recently, had no domestic option that offered it.
Closing
This is the first of four pieces on what coordinated care actually looks like in Nigerian practice. The next will argue that the diagnostic and surgical infrastructure built without these systems is a less complete answer than it appears to be — that an excellent procedure with no follow-up is, over the timescale of a patient’s actual life, a partial intervention.
For now the relevant point is narrower. The cost of poor follow-up in Nigeria is not measured in inconvenience. It is measured in the second stent, the second-stage cancer, the second admission that should have been a clinic visit, and the families who realise too late that the system they trusted had quietly stopped knowing their relative’s name. None of those costs is necessary. All of them are avoidable. What they require is the part of medicine that the default model has never built — the part that happens after the discharge, in the months and the years, in the chart that is read in sequence, by the clinician who remembers.
The first conversation is private and costs nothing.